Geneva Score for VTE Prophylaxis
Identification of acutely ill medical patients requiring thromboprophylaxis
Low risk
VTE prophylaxis generally not recommended
NaN
Dodatne informacije
Opozorilo
Orodje je namenjeno zgolj v izobraževalne namene in ne predstavlja strokovnega nasveta ali nadomestka za strokovni nasvet. Orodja ni dovoljeno uporabljati za podajo medicinske diagnoze in/ali medicinsko zdravljenje.
General description
Venous thromboembolism (VTE) is one of the most common cardiovascular diseases and about 50% of all VTE events occur as a result of a hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures reducing the rate of symptomatic VTE by half.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.
Venous thromboembolism (VTE) is one of the most common cardiovascular diseases and about 50% of all VTE events occur as a result of a hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures reducing the rate of symptomatic VTE by half.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.
Result ranges
Low risk
VTE prophylaxis generally not recommended
0–3VTE prophylaxis generally not recommended
High risk
VTE prophylaxis generally recommended
≥ 3VTE prophylaxis generally recommended
Formula
Cardiac failure, respiratory failure, recent stroke, recent myocardial infarction, acute infection/sepsis, acute rheumatic disease, active malignancy, myeloproliferative syndrome, nephrotic syndrome, history of VTE, known thrombophilia are assigned 2 points if they are answered yes. The rest are assigned 1 point if answered yes. All questions are assigned 0 points if answered no.
References
Chopard, P et al. “Identifying acutely ill medical patients requiring thromboprophylaxis.” Journal of thrombosis and haemostasis : JTH vol. 4,4 (2006): 915-6. doi:10.1111/j.1538-7836.2006.01818.x
Nendaz, M et al. “Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE).” Thrombosis and haemostasis vol. 111,3 (2014): 531-8. doi:10.1160/TH13-05-0427
Verzija
1
O tem orodju
Venous thromboembolism (VTE) is one of the most common cardiovascular diseases and about 50% of all VTE events occur as a result of a hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures reducing the rate of symptomatic VTE by half.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.
